Medical Device Clinical Trials Market: as NAMSA absorbs Labcorp's entire early-development medical device testing business, the specialist device-focused CRO segment is consolidating capability that used to sit inside a diversified diagnostics conglomerate into a single organisation built exclusively around device sponsors, so the competitive question for device manufacturers choosing a research partner is shifting from which large, multi-industry CRO to select toward whether a device-dedicated specialist can now offer the full biocompatibility-through-clinical continuum that used to require multiple vendor relationships.

The global medical device clinical trials market size was USD 17.72 Billion in 2025 and is expected to register a revenue CAGR of 6.5% during the forecast period. Market revenue growth is driven by factors such as sustained global medical device pipeline volume requiring pivotal and post-market clinical evidence, device-focused CRO specialisation consolidating capability across the biocompatibility-through-clinical development continuum, and decentralised and hybrid trial technology expanding patient access to device clinical studies. The first driving factor is the sustained scale of the global medical device development pipeline, which requires pivotal clinical evidence for FDA and EU MDR regulatory pathways across an expanding range of device categories. Contract research organisations account for approximately 55% of total 2025 market revenue, reflecting the extent to which device manufacturers outsource clinical trial execution rather than conducting studies entirely in-house. The second driving factor is device-focused CRO specialisation, as dedicated medical device research organisations consolidate capability spanning biocompatibility testing through pivotal clinical trial execution. The third driving factor is decentralised and hybrid trial technology, which expands patient access to device clinical studies beyond traditional site-based recruitment models. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a device-focused CRO's acquisition of an adjacent specialist capability converts a narrower service offering into a fuller biocompatibility-through-clinical development continuum, which lets that CRO capture a device sponsor's spend across multiple previously separate vendor relationships within one organisation. Because a device sponsor moving a product from early feasibility through pivotal trial and into post-market follow-up study historically needed to coordinate across separate preclinical testing, biocompatibility, and clinical trial execution vendors, a CRO that consolidates these capabilities under one organisation captures a sponsor's spend across the full development continuum rather than a single isolated study, so acquisition-driven capability consolidation compounds revenue capture per sponsor relationship. As a result, demand and revenue share are concentrating around device-focused CROs with the broadest consolidated service continuum, and the forecast tilts toward specialists who can offer sponsors a single coordinated relationship rather than multi-industry generalist CROs competing primarily on scale alone. For instance, in January 2026, NAMSA completed the acquisition of the early development medical device testing business of Labcorp, adding biocompatibility, microbiological, analytical testing, and preclinical research capability to its existing clinical research and regulatory consulting services, extending its continuum coverage for more than 3,000 MedTech sponsor relationships globally. These are some of the key factors driving revenue growth of the market.

Because device clinical trial patient recruitment often targets narrower, more specific patient populations than typical pharmaceutical trials, particularly for niche device indications, enrollment timelines carry genuine unpredictability that can extend a study's overall timeline and cost well beyond initial planning estimates regardless of the CRO's operational efficiency.

Increasingly stringent EU MDR clinical evidence requirements are a second constraint, because the EU Medical Device Regulation has meaningfully raised the clinical evidence bar for CE marking relative to the prior Medical Device Directive framework, which has lengthened study timelines and increased trial costs for device sponsors seeking European market access.

Site capacity and investigator availability constraints are a third constraint, since the supply of clinical sites and investigators experienced in device-specific trial protocols has not scaled proportionally with rising device trial volume, which can create site-level bottlenecks independent of a CRO's own operational capacity.

These factors substantially limit medical device clinical trials market growth over the forecast period.

The clearest driver of demand is the sustained scale of the global medical device development pipeline, which requires pivotal clinical evidence for FDA and EU MDR regulatory pathways across an expanding range of device categories. A growing share of novel medical devices, particularly software-driven and higher-risk implantable categories, now require clinical evidence beyond what substantial equivalence alone can establish, so the underlying volume of studies requiring full clinical trial execution grows even as the total device pipeline itself expands. Contract research organisations account for approximately 55% of total 2025 market revenue, and IQVIA reported R&D Solutions segment revenue of USD 8.53 billion in fiscal year 2024, while ICON plc reported fiscal year 2024 revenue of USD 8.28 billion. The effect on the market is that baseline device clinical trial demand tracks the underlying device development pipeline directly, providing a demand base independent of any single CRO's competitive positioning. These are some of the key factors driving revenue growth of the market.

The second driver is device-focused CRO specialisation, as dedicated medical device research organisations consolidate capability spanning biocompatibility testing through pivotal clinical trial execution under a single organisation. A device sponsor moving a product from early feasibility through pivotal trial and into post-market follow-up study benefits from coordinating that full continuum through a single organisation with device-specific expertise, rather than managing separate vendor relationships for preclinical testing, biocompatibility validation, and clinical trial execution. In January 2026, NAMSA completed the acquisition of the early development medical device testing business of Labcorp, adding biocompatibility, microbiological, and analytical testing capability to its existing clinical research and regulatory consulting services, following its January 2025 acquisition of WuXi AppTec's US-based medical device testing operations. The effect on the market is that device-dedicated CRO specialists are increasingly able to offer sponsors the same full-continuum coverage that previously required either a large multi-industry generalist CRO or multiple separate specialist vendor relationships. These are some of the key factors driving revenue growth of the market.

NAMSA's acquisition of Labcorp's early development medical device testing business marks its tenth acquisition since joining ARCHIMED in 2020. A specialist device-focused CRO is now assembling the full biocompatibility-through-clinical continuum that used to require multiple vendor relationships.

The third driver is decentralised and hybrid trial technology, which expands patient access to device clinical studies beyond the constraints of traditional site-based recruitment models. A device trial that requires patients to travel repeatedly to a limited number of specialist sites can face significant recruitment and retention challenges, so decentralised elements that let patients participate partially or fully outside a traditional clinical site can widen the eligible patient population and improve enrollment timeline predictability. The effect on the market is that trial design flexibility incorporating decentralised elements is becoming a genuine differentiator for CROs competing to win sponsor trial execution contracts, particularly for device categories with geographically dispersed target patient populations. These are some of the key factors driving revenue growth of the market.

However, the medical device clinical trials market faces severe adoption constraints from patient recruitment and enrollment timeline unpredictability and increasingly stringent EU MDR clinical evidence requirements that lengthen study timelines.

Because device clinical trial patient recruitment often targets narrower, more specific patient populations than typical pharmaceutical trials, particularly for niche device indications, enrollment timelines carry genuine unpredictability that can extend a study's overall timeline and cost well beyond initial planning estimates regardless of the CRO's operational efficiency, even with decentralised trial technology helping to widen the eligible population.

Increasingly stringent EU MDR clinical evidence requirements compound this, because the EU Medical Device Regulation has meaningfully raised the clinical evidence bar for CE marking relative to the prior Medical Device Directive framework, which has lengthened study timelines and increased trial costs for device sponsors seeking European market access.

Site capacity and investigator availability constraints are the third constraint, since the supply of clinical sites and investigators experienced in device-specific trial protocols has not scaled proportionally with rising device trial volume, which can create site-level bottlenecks independent of a CRO's own operational capacity, even for well-resourced, full-continuum specialists like NAMSA following its expanded acquisitions.

These factors substantially limit medical device clinical trials market growth over the forecast period.

Based on study type, the global medical device clinical trials market is segmented into pivotal studies, post-market clinical follow-up, and early feasibility or first-in-human studies. Pivotal studies hold the largest revenue share, because FDA 510(k) substantial equivalence, PMA IDE, and EU MDR clinical evaluation pathways collectively require the most extensive and highest-cost clinical evidence generation of any study type, which suits a market where regulatory-pathway-defining studies command the largest revenue category. Post-market clinical follow-up is expected to register the fastest revenue growth rate in the global medical device clinical trials market over the forecast period, driven by EU MDR's expanded post-market surveillance requirements creating sustained demand for ongoing clinical evidence generation beyond initial market approval.

Clinical monitoring service is expected to account for the largest revenue share in the global medical device clinical trials market during the forecast period

Based on service, the global medical device clinical trials market is segmented into clinical monitoring, regulatory affairs and medical writing, biocompatibility and preclinical testing, data management and biostatistics, and site management and patient recruitment. Clinical monitoring holds the largest revenue share, because ongoing site oversight and protocol compliance verification represents the most labour-intensive and continuous service category across a study's full execution timeline. Biocompatibility and preclinical testing is expected to register the fastest revenue growth rate in the global medical device clinical trials market over the forecast period, driven by NAMSA's expanded testing capability following its Labcorp and WuXi AppTec acquisitions.

Based on device, the global medical device clinical trials market is segmented into cardiovascular, orthopedic and spine, neurological and neurovascular, and diagnostic and digital health devices. Cardiovascular devices hold the largest revenue share, because stents, pacemakers, valves, and EP catheters collectively represent the highest-volume and most clinically complex device trial category, requiring extensive pivotal and post-market evidence generation. Diagnostic and digital health devices are expected to register the fastest revenue growth rate in the global medical device clinical trials market over the forecast period, driven by Parexel's Digital Health unit and comparable software-as-medical-device-focused clinical validation and regulatory strategy service offerings.

Based on regional analysis, the medical device clinical trials market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA pivotal study activity and the largest device-focused CRO headquarters base creates the deepest clinical trial execution market globally, and because IQVIA, ICON, and NAMSA all maintain their primary commercial presence in the US market. NAMSA's completed acquisition of Labcorp's early development testing business specifically reinforces the depth of US-based biocompatibility and preclinical testing capacity. The concentration of FDA regulatory pathway activity in the country also means new device clinical trial designs are typically executed in the United States first, before international expansion.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national markets within Europe. The EU Medical Device Regulation's expanded clinical evidence requirements have made the region a more demanding but still substantial trial execution market. The result is steady rather than rapid growth, shaped more by EU MDR compliance timelines than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, driven by expanding domestic device manufacturing and increasing regional clinical trial capacity. Medpace's Singapore clinical research facility, opened in January 2024 for cardiovascular and neurological device trials, reflects the region's growing role as a device-specialist trial execution hub, leaving considerably more room for growth than in the already trial-execution-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding clinical trial site infrastructure driving early demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised trial equipment and biocompatibility testing materials that Latin American clinical research sites depend on, an effect expected to run through 2026 and slow medical device clinical trial capacity expansion beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding clinical research infrastructure investment and the UAE's regional distribution hubs represent the primary investment centres for medical device clinical trial capacity. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the specialist trial site infrastructure needed to support device-specific clinical research at scale.